Blog

New Hope for Mantle Cell Lymphoma Patients – The Babak Lab

Maria (Masha) Babak/LinkedIn

Nov 21, 2024, 09:55

New Hope for Mantle Cell Lymphoma Patients – The Babak Lab

The Babak Lab shared a post on LinkedIn:

“FDA Approval Alert: New Hope for Mantle Cell Lymphoma Patients

On May 30, 2024, the FDA approved lisocabtagene maraleucel (Breyanzi), a CAR T-cell therapy, for adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two prior treatments, including a BTK inhibitor.

Key Highlights:

100% Effectiveness
85.3% overall response rate (ORR).
67.6% complete response rate (CRR).
Median response duration: 13.3 months.

Trial Insights: Patients with PET-positive disease were treated after lymphodepleting chemotherapy.
Demonstrated benefits for heavily pretreated patients.

Safety Considerations: Risks include cytokine release syndrome (CRS) and neurologic toxicities, requiring close monitoring.

This milestone is a testament to advances in CAR T-cell therapy, providing new options for those with limited alternatives.

Let’s continue the conversation about how innovative treatments are shaping the future of oncology. Share your thoughts below!”

Read further.

Maria Babak, Head of The Babak Lab, shared this post, adding:

“This FDA’s approval of lisocabtagene maraleucel offers new hope for patients with relapsed or refractory mantle cell lymphoma. Innovations like this remind us how science continues to push boundaries and improve lives.”

New Hope for Mantle Cell Lymphoma Patients - The Babak Lab

More posts featuring The Babak Lab and Maria Babak.

Dr. Maria (Masha) Babak is the Head of The Babak Lab and an Assistant Professor at the City University of Hong Kong. In November 2020, she joined the City University of Hong Kong as an assistant professor. Dr. Babak received the Graeme Hanson-AsBIC Early Career Award in 2022.

Her research interests are at the intersection of chemistry, biology, and medicine, with a focus on the discovery and preclinical development of anticancer drugs for resistant and aggressive cancers with limited treatment options, such as malignant pleural mesothelioma and brain metastases. She received the Yvonne Award by OncoDaily in the “mentorship” category.